RCT | Momelotinib vs. danazol in symptomatic patients with anemia and myelofibrosis

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study – The Lancet (link to abstract – $ for full-text)

News Release: Targeted therapy momelotinib provides significant symptom and anemia improvements in patients with myelofibrosis – University of Texas M. D. Anderson Cancer Center